Heart failure (HF) is not uncommon among patients with hematologic malignancies (HM) undergoing hematopoietic stem cell transplantation (HSCT) and is associated with an increased mortality. Among HSCT patients without signs or symptoms of HF, groups with elevated and normal N-terminal probrain natriuretic peptide (NT-proBNP) levels have been poorly characterized in previous literature. Herein, we reviewed consecutive admissions for HM undergoing HSCT (). Based on NT-proBNP levels and clinical signs or symptoms of HF at follow-up (one month after HSCT), patients were grouped into ENPH (elevated , presence of HF symptoms or signs), ENAH (elevated , absence of HF symptoms or signs), and NN (normal ). ENPH, ENAH, and NN were observed in 22.9%, 54.5%, and 22.6% of patients, respectively. ENPH patients had a significantly higher baseline NT-proBNP level, followed by the ENAH and NN groups, respectively (). Frequencies of HLA partially matched related donors, stem cell source (bone marrow+peripheral blood), and utilization of graft-versus-host disease prophylaxis regimens (ciclosporin+methotrexate+antithymocyte globulin±mycophenolate mofetil) were also the highest in the ENPH group, followed by ENAH and NN groups, respectively (all ). Uric acid and hemoglobin levels, transplant type, and cyclophosphamide-based conditioning regimens utilized were similar between the ENAH and ENPH groups. We found that ENPH and ENAH are commonly observed in HM hospitalized for HSCT. Serum NT-proBNP levels may allow for earlier identification of HSCT patients at high risk of developing cardiac dysfunction.

中文翻译：

---

造血干细胞移植后不同N端脑钠肽前脑肽水平患者的临床特征

心力衰竭 (HF) 在接受造血干细胞移植 (HSCT) 的血液系统恶性肿瘤 (HM) 患者中并不少见，并且与死亡率增加有关。在没有 HF 体征或症状的 HSCT 患者中，N 端脑钠肽原 (NT-proBNP) 水平升高和正常的组在以前的文献中没有得到很好的描述。在此，我们回顾了 HM 接受 HSCT 的连续入院（）。基于NT-proBNP水平，并在后续（HSCT后一个月），临床症状或心衰症状，患者被分为ENPH（ ē levated， p的resence ħ ˚F症状或体征），ENAH（ ê levated， 一个的bsence ħ ˚F症状或体征），和NN（ Ñ ormal）。ENPH、ENAH 和 NN 分别在 22.9%、54.5% 和 22.6% 的患者中观察到。ENPH 患者的基线 NT-proBNP 水平显着升高，其次是 ENAH 和 NN 组（）。HLA部分匹配的相关供体、干细胞来源（骨髓+外周血）和移植物抗宿主病预防方案（环孢素+甲氨蝶呤+抗胸腺细胞球蛋白±霉酚酸酯）的使用率在ENPH组中也是最高的，其次是 ENAH 和 NN 组（所有）。ENAH 和 ENPH 组之间的尿酸和血红蛋白水平、移植类型和基于环磷酰胺的预处理方案相似。我们发现 ENPH 和 ENAH 在因 HSCT 住院的 HM 中很常见。血清 NT-proBNP 水平可能有助于更早识别发生心功能不全的高风险 HSCT 患者。